कीमोथेरेपी: ओपन एक्सेस
खुला एक्सेस

अमूर्त

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Caibao Jin, Qing Li, Xiaojian Zhu and Li Meng

Stopping tyrosine kinase inhibitors (TKIs) treatment is an emerging goal of chronic myeloid leukemia (CML) management. Several studies have demonstrated the feasibility of stopping treatment. A sustained molecular response on long-term TKIs therapy seems to be necessary prior to attempting treatment-free remission (TFR). However, there were none available characteristics or indicators which can predict the outcome of TKIs discontinuation now. In our opinion, factors which could reflex the progression probability of minimal residual leukemia such as leukemia stem cells and microenvironment might play a pivotal role. Besides, novel methods for further monitoring would also attract much attention of the researchers in this area.